However, compared with docetaxel, the patients receiving PD-1/PD-L1 antibodies showed significant decrease in the incidence rate of grade 1-4 AEs such as nausea, febrile neutropenia, diarrhea, anemia, neutropenia, fatigue and alopecia (nausea: RR 0.58, 95% CI: 0.46-0.75, P < 0.001; febrile neutropenia: RR 0.02, 95% CI: 0.01-0.06, P < 0.001; diarrhea: RR 0.41, 95% CI: 0.31-0.55; neutropenia: RR 0.04, 95% CI: 0.02-0.10, P < 0.001; anemia: RR 0.25, 95% CI: 0.14-0.42, P < 0.001; fatigue: RR 0.63, 95% CI: 0.56-0.71, P < 0.001; alopecia: RR 0.02, 95% CI: 0.01-0.04, P < 0.001). This evidence concerns the gene PDCD1 and Nausea.